ANAB
ANAPTYSBIO, INC
NASDAQ · Healthcare · Biotechnology · US
$48.28
−0.74%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 237.6M | 234.6M | 91.3M | 17.2M | 10.3M |
| Cost of Revenue | (73.3M) | 2.4M | 163.8M | 132.3M | 88.8M |
| Gross Profit | 316.3M | 232.2M | (72.6M) | (115.1M) | (78.5M) |
| Operating Expenses | |||||
| R&D Expense | 93.5M | 136.0M | 163.8M | 139.6M | 88.8M |
| SG&A Expense | 68.2M | 50.7M | 42.4M | 41.9M | 36.6M |
| General & Admin Expense | 68.2M | 50.7M | 42.4M | 41.9M | 36.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 68.0M | (2.4M) | (163.8M) | (132.3M) | (88.8M) |
| Total Operating Expenses | 229.8M | 184.3M | 42.4M | 49.3M | 36.6M |
| Cost and Expenses | 156.5M | 186.7M | 206.2M | 181.6M | 125.4M |
| Operating Income (EBIT) | 133.9M | 47.9M | (114.9M) | (164.4M) | (115.2M) |
| Non-Operating | |||||
| Interest Income | 8.7M | 13.5M | 19.8M | 18.9M | 7.5M |
| Interest Expense | 83.4M | 79.9M | 50.1M | 18.1M | 21.1M |
| Net Interest Income | (74.7M) | (66.4M) | (30.3M) | 790.0K | (13.6M) |
| Other Non-Op Income/Expense | (74.2M) | (61.0M) | (30.3M) | 788.0K | (13.5M) |
| Non-Operating Income (excl Interest) | (8.1M) | (18.9M) | (19.8M) | (7.3M) | (7.6M) |
| EBT (Pre-Tax Income) | 59.7M | (13.1M) | (145.2M) | (163.6M) | (128.7M) |
| Income Tax Expense | (181.4M) | 164.0K | 3.0K | (4.0K) | 24.0K |
| Bottom Line | |||||
| Net Income | 195.7M | (13.2M) | (145.2M) | (163.6M) | (128.7M) |
| Earnings from Cont. Ops | 241.1M | (13.2M) | (145.2M) | (163.6M) | (128.7M) |
| Earnings from Discont. Ops | (45.4M) | — | — | — | — |
| Bottom Line Net Income | 195.7M | (13.2M) | (145.2M) | (163.6M) | (128.7M) |
| Per Share | |||||
| Basic EPS | $6.75 | ($0.46) | ($5.12) | ($6.08) | ($4.57) |
| Diluted EPS | $5.37 | ($0.46) | ($5.12) | ($6.08) | ($4.57) |
| Revenue Per Share | $8.12 | $8.44 | $3.22 | $0.64 | $0.37 |
| Shares | |||||
| Basic Shares Outstanding | 29.3M | 27.8M | 28.4M | 26.9M | 28.2M |
| Diluted Shares Outstanding | 36.0M | 31.3M | 28.4M | 26.9M | 28.2M |
| Profitability Metrics | |||||
| EBITDA | 91.9M | 69.2M | (92.7M) | (154.7M) | (105.3M) |
| D&A | 2.2M | 2.4M | 2.4M | 2.4M | 2.3M |
| EBIT | 89.7M | 66.8M | (95.1M) | (157.1M) | (107.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026